WNK4: Difference between revisions
CSV import |
CSV import |
||
| Line 29: | Line 29: | ||
{{protein-stub}} | {{protein-stub}} | ||
{{medicine-stub}} | {{medicine-stub}} | ||
<gallery> | |||
File:Figure_1._Domain_structure_of_WNK4_and_the_positions_of_the_initially_identified_PHAII-causing_mutations._.jpg|Domain structure of WNK4 and the positions of the initially identified PHAII-causing mutations | |||
File:Kinase_Wiki.jpg|WNK4 | |||
File:WNK4_PHAII.jpg|WNK4 | |||
File:Na_K.jpg|WNK4 | |||
</gallery> | |||
Latest revision as of 05:02, 18 February 2025
WNK4 (With No Lysine (K) 4) is a protein that in humans is encoded by the WNK4 gene. It is a member of the WNK family of serine-threonine kinases, which are known for their unusual placement of the catalytic lysine. WNK4 plays a crucial role in maintaining potassium balance and blood pressure regulation in the body.
Function[edit]
WNK4 is primarily expressed in the kidney and plays a significant role in the regulation of ion transport across cell membranes. It influences the activity of several ion channels and transporters, including the thiazide-sensitive Na-Cl cotransporter (NCC), the epithelial sodium channel (ENaC), and the renal outer medullary potassium channel (ROMK).
Clinical significance[edit]
Mutations in the WNK4 gene can lead to a rare form of hypertension known as pseudohypoaldosteronism type II (PHAII), also known as Gordon's syndrome. This condition is characterized by high blood pressure, increased levels of potassium in the blood (hyperkalemia), and metabolic acidosis.
Research[edit]
Research into WNK4 has potential implications for the treatment of diseases such as hypertension and kidney disease. Understanding the mechanisms by which WNK4 regulates ion transport could lead to the development of new therapeutic strategies.
See also[edit]
References[edit]
<references group="" responsive="1"></references>
-
Domain structure of WNK4 and the positions of the initially identified PHAII-causing mutations
-
WNK4
-
WNK4
-
WNK4

